Randall Huling, MD
Family Medicine · Olive Branch, MSNPI 1316936917
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $14,779 of the $22,974 with a category attached, or 64.3%. Eli Lilly accounts for 61.3% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $13,903 and has fallen 98.4% since, to $229 in 2025. Among family medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 258 payments — averaging $89.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$14K
- Amgen$4K
- Janssen Research & Development, LLC$1K
- Medtronic$986
- Novo Nordisk$675
- Amarin Pharma, Inc.$289
- plus $2K from 25 others
Across 459 payments — averaging $10,039 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.6M
- Regeneron$1.3M
- AbbVie$409K
- AstraZeneca$332K
- Partner Therapeutics, Inc.$323K
- Janssen Research & Development, LLC$215K
- plus $424K from 12 others
What the payments were for
- Consulting fees$4,30019%
- Travel & lodging$14,77964%
- Food & beverage$3,88617%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 69 | $14,092 |
| Amgen | 2 | $4,300 |
| Janssen Research & Development, LLC | 9 | $1,056 |
| Medtronic | 6 | $986 |
| Novo Nordisk | 56 | $675 |
| Amarin Pharma, Inc. | 17 | $289 |
| AstraZeneca | 16 | $285 |
| Pfizer | 12 | $185 |
| AbbVie(2 entities) | 9 | $166 |
| Abbott | 9 | $137 |
| Bayer | 6 | $101 |
| Lilly USA, LLC | 9 | $70 |
| Boston Scientific | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $55 |
| Boehringer Ingelheim | 3 | $54 |
| Halozyme Inc | 3 | $54 |
| Merck | 4 | $54 |
| Currax Pharmaceuticals LLC | 3 | $40 |
| Corcept Therapeutics | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 3 | $31 |
| Edwards Lifesciences | 1 | $29 |
| Ardelyx, Inc. | 1 | $29 |
| Averitas Pharma Inc. | 1 | $24 |
| Sanofi Pasteur Inc. | 2 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Nevro Corp. | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Quidel Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,974 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 45 | $63,422 |
| EliquisApixaban | 79 | $61,913 |
| OzempicSemaglutide | 16 | $33,226 |
| JardianceEmpagliflozin | 31 | $32,761 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 98 | $22,112 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $21,303 |
| FarxigaDapagliflozin Propanediol | 24 | $16,768 |
| LinzessLinaclotide | 19 | $16,450 |
| MounjaroTirzepatide | 13 | $15,323 |
| XareltoRivaroxaban | 16 | $12,449 |
| MyrbetriqMirabegron | 18 | $9,878 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 29 | $9,047 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $8,143 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $7,565 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $2,990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $70 | $78,74558 claims |
| PfizerEliquis | $185 | $61,91379 claims |
| Novo NordiskOzempic | $675 | $33,22616 claims |
| Boehringer IngelheimJardiance | $54 | $32,76131 claims |
| AbbVieLinzess, Synthroid | $166 | $17,77935 claims |
| AstraZenecaFarxiga | $285 | $16,76824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Olive Branch
- Russell CarlisleWesson$1.6M
- Keith StokesLexington$654K
- Walter CarnahanSouthaven$146K
- Karen WhitneyWhitfield$117K
- Dava ClevelandJackson$100K
- Andrea PhillipsJackson$96K
- Kristi TrimmRidgeland$34K
- Tana CooperBiloxi$25K
- Delora DenneyPicayune$24K
- Timothy QuinnRidgeland$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.